BR112018016734A2 - peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres - Google Patents

peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres

Info

Publication number
BR112018016734A2
BR112018016734A2 BR112018016734A BR112018016734A BR112018016734A2 BR 112018016734 A2 BR112018016734 A2 BR 112018016734A2 BR 112018016734 A BR112018016734 A BR 112018016734A BR 112018016734 A BR112018016734 A BR 112018016734A BR 112018016734 A2 BR112018016734 A2 BR 112018016734A2
Authority
BR
Brazil
Prior art keywords
peptides
cells
relates
cancers
present
Prior art date
Application number
BR112018016734A
Other languages
English (en)
Inventor
Mahr Andrea
Song Colette
Singh Harpreet
fritsche Jens
Schoor Oliver
Weinschenk Toni
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of BR112018016734A2 publication Critical patent/BR112018016734A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/836—Intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

a presente invenção refere-se a peptídeos, proteínas, ácidos nucleicos e células para utilização em métodos de imunoterapia. mais especificamente, a presente invenção refere-se à imunoterapia do câncer. a presente invenção refere-se também a epítopos de peptídeos obtidos de células t associadas a tumores, isoladamente ou combinados com outros peptídeos associados a tumores, que podem, por exemplo, atuar como ingredientes farmacêuticos ativos de composições vacinais que estimulam respostas imunes antitumorais ou que estimulam células t ex vivo, que são depois transferidas a pacientes. peptídeos, quer ligados a moléculas do complexo principal de histocompatibilidade (mhc) ou peptídeos como tal, também podem ser alvos de anticorpos, de receptores de células t solúveis e de outras moléculas ligantes.
BR112018016734A 2016-03-01 2017-02-28 peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres BR112018016734A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302010P 2016-03-01 2016-03-01
GBGB1603568.5A GB201603568D0 (en) 2016-03-01 2016-03-01 Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
PCT/EP2017/054559 WO2017148888A1 (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers

Publications (1)

Publication Number Publication Date
BR112018016734A2 true BR112018016734A2 (pt) 2018-12-26

Family

ID=55807140

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016734A BR112018016734A2 (pt) 2016-03-01 2017-02-28 peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres

Country Status (18)

Country Link
US (1) US10400011B2 (pt)
EP (2) EP3915577A1 (pt)
JP (2) JP2019516663A (pt)
KR (1) KR20180118702A (pt)
CN (1) CN109152825A (pt)
AU (2) AU2017227967B2 (pt)
BR (1) BR112018016734A2 (pt)
CA (1) CA3014848A1 (pt)
CO (1) CO2018008763A2 (pt)
CR (4) CR20210034A (pt)
EA (1) EA201891670A1 (pt)
GB (1) GB201603568D0 (pt)
IL (1) IL261266B2 (pt)
MA (2) MA43690A (pt)
MX (1) MX2018010167A (pt)
SG (3) SG11201806951TA (pt)
TW (1) TWI641617B (pt)
WO (1) WO2017148888A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
CA3048448A1 (en) 2016-12-28 2018-07-05 Invvax, Inc. Influenza vaccines
HRP20211744T1 (hr) 2017-07-14 2022-02-04 Immatics Biotechnologies Gmbh Poboljšana molekula polipeptida dvostruke specifičnosti
CA3083242A1 (en) * 2017-11-21 2019-05-31 Naofumi MIWA Human cancer cell metastasis inhibitory agent and human cancer cell determination agent
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
MA51792A (fr) 2018-02-09 2020-12-16 Immatics Us Inc Procédés de fabrication de lymphocytes t
US20210363215A1 (en) * 2018-04-19 2021-11-25 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
CN109801270B (zh) 2018-12-29 2021-07-16 北京市商汤科技开发有限公司 锚点确定方法及装置、电子设备和存储介质
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
PE20220164A1 (es) 2019-05-27 2022-01-28 Immatics Us Inc Vectores viricos y uso de los mismos en terapias celulares adoptivas
BR112021024540A2 (pt) 2019-06-06 2022-03-22 Immatics Biotechnologies Gmbh Métodos para selecionar uma célula ou um vírus, determinar a sequência de um ácido nucleico, produzir uma célula que expressa um ácido nucleico e tratar um sujeito, célula imune selecionada e método para selecionar uma célula imune
CN114269357A (zh) * 2019-06-12 2022-04-01 百欧恩泰美国公司 新抗原组合物及其用途
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN111118011B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0027478表达的siRNA及其应用
MX2022010461A (es) 2020-02-24 2022-12-13 Immatics Us Inc Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas.
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
US20220356252A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
WO2023025851A1 (en) 2021-08-24 2023-03-02 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
US20230145121A1 (en) * 2021-08-31 2023-05-11 Washington University Neoantigen vaccines for triple negative breast cancer
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212697A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN115785206B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标07及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002086443A2 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2003104429A2 (en) 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
PT1806359E (pt) * 2005-09-05 2010-05-25 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
KR100906145B1 (ko) * 2006-05-30 2009-07-03 한국생명공학연구원 Ｔｍｐｒｓｓ4 억제제를 유효성분으로 포함하는 항암제
KR101778174B1 (ko) * 2006-07-05 2017-09-13 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
EP2336771A1 (en) * 2009-12-16 2011-06-22 Universität Duisburg-Essen HAS3v2 as tumor marker
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201511792D0 (en) * 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers

Also Published As

Publication number Publication date
CO2018008763A2 (es) 2018-08-31
EP3915577A1 (en) 2021-12-01
CR20210035A (es) 2021-02-10
KR20180118702A (ko) 2018-10-31
IL261266A (en) 2018-10-31
IL261266B1 (en) 2023-06-01
SG11201806951TA (en) 2018-09-27
MA43090A1 (fr) 2018-10-31
CA3014848A1 (en) 2017-09-08
IL261266B2 (en) 2023-10-01
CR20210033A (es) 2021-02-10
EP3423085A1 (en) 2019-01-09
JP2019516663A (ja) 2019-06-20
SG10202110228YA (en) 2021-10-28
MX2018010167A (es) 2018-11-29
CR20210034A (es) 2021-02-10
EA201891670A1 (ru) 2019-02-28
AU2021204201A1 (en) 2021-07-15
AU2017227967A1 (en) 2018-09-06
US10400011B2 (en) 2019-09-03
GB201603568D0 (en) 2016-04-13
US20170253633A1 (en) 2017-09-07
TWI641617B (zh) 2018-11-21
CR20180398A (es) 2018-11-30
AU2021204201B2 (en) 2023-04-13
JP2021129580A (ja) 2021-09-09
CN109152825A (zh) 2019-01-04
JP7201740B2 (ja) 2023-01-10
WO2017148888A1 (en) 2017-09-08
AU2017227967B2 (en) 2021-03-25
MA43690A (fr) 2021-06-02
TW201734039A (zh) 2017-10-01
SG10202008107QA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
BR112018016734A2 (pt) peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres
BR112018015793A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia contra nhl e de outros cânceres
BR112017027459A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de ovário e outros cânceres
BR112018001687A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de próstata e outros cânceres
BR112018009980A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de mama e outros cânceres
BR112018008806A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia de diversos cânceres
BR112017028558A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer epitelial de ovário e outros cânceres
BR112018017022A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão de células não pequenas e outros cânceres
BR112017017289A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra diversos tumores
BR112017027639A2 (pt) epítopos celulares e combinações de epítopos celulares para emprego na imunoterapia de mieloma e outros cânceres
BR112018003460A2 (pt) peptídeos, combinações de peptídeos e suportes para emprego na imunoterapia de diversos cânceres
BR112017019217A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pâncreas e outros cânceres
BR112017017560A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pulmão, incluindo cpcnp e outros câncere
BR112017019804A2 (pt) peptídeos e combinações de peptídeos e arcabouços para uso na imunoterapia contra o carcinoma de células renais (ccr) e outros cânceres
BR112018007206A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra leucemia linfocítica crônica (cll) e outros cânceres
BR112018015545A2 (pt) tratamentos de câncer do útero
BR112017023362A2 (pt) peptídeos e combinação de peptídeos e arcabouços dos mesmos para uso na imunoterapia contra o carcinoma colorretal (crc) e outros cânceres
BR112018067989A2 (pt) células t transfectadas e receptores de células t para uso em imunoterapia anticâncer
BR122020014377A8 (pt) Peptídeo, anticorpo, receptor de célula t, aptâmero, ácido nucleico, célula hospedeira recombinante, método in vitro de produção de linfócitos t ativados, linfócito t ativado, composição farmacêutica, método de produção do peptídeo, uso de um número eficaz de células t ativadas, uso do peptídeo, kit e método in vitro de produção de uma vacina anticâncer personalizada
BR112017028363A2 (pt) peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de esôfago e outros cânceres
BR112018068489A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia anticâncer
BR112018073921A2 (pt) peptídeos e combinações de peptídeos que servem como alvos e para uso na imunoterapia do câncer da vesícula biliar, do colangiocarcinoma e de outros cânceres
CO2019012077A2 (es) Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer
BR112018070873A2 (pt) imunoterapia contra melanoma e outros cânceres
BR112019028070A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão, incluindo cpcnp, cppc e outros cânceres

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements